Supernus Pharmaceuticals Announces Board Changes
Ticker: SUPN · Form: 8-K · Filed: Apr 24, 2024 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | 8-K |
| Filed Date | Apr 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-of-directors, executive-compensation, governance
Related Tickers: SUPN
TL;DR
Board shuffle at Supernus: new directors elected, exec comp details released.
AI Summary
On April 22, 2024, Supernus Pharmaceuticals, Inc. announced changes to its Board of Directors, including the election of Dr. Elizabeth H. Shea and Mr. David M. Neuwirth as Class II directors. Additionally, the company reported on compensatory arrangements for its named executive officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing primarily concerns routine board appointments and executive compensation disclosures, which are standard corporate governance events.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- Dr. Elizabeth H. Shea (person) — Elected Class II Director
- Mr. David M. Neuwirth (person) — Elected Class II Director
- April 22, 2024 (date) — Date of earliest event reported
FAQ
Who were the newly elected directors at Supernus Pharmaceuticals, Inc.?
Dr. Elizabeth H. Shea and Mr. David M. Neuwirth were elected as Class II directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is April 22, 2024.
What type of information is disclosed regarding executive compensation?
The filing reports on compensatory arrangements of certain officers.
In which state was Supernus Pharmaceuticals, Inc. incorporated?
Supernus Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal executive office address for Supernus Pharmaceuticals, Inc.?
The principal executive office is located at 9715 Key West Ave, Rockville, MD 20850.
Filing Stats: 473 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-04-24 16:05:29
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20240422.htm (8-K) — 25KB
- 0001356576-24-000020.txt ( ) — 145KB
- supn-20240422.xsd (EX-101.SCH) — 2KB
- supn-20240422_lab.xml (EX-101.LAB) — 21KB
- supn-20240422_pre.xml (EX-101.PRE) — 12KB
- supn-20240422_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On April 22, 2024, John M. Siebert, Ph.D. informed Supernus Pharmaceuticals, Inc. (the "Company") that he has decided to retire from the Company's Board of Directors (the "Board"), effective at the Company's Annual Meeting of Stockholders in June 2024 (the "Annual Meeting"), and therefore is not standing for re-election at the Annual Meeting. He indicated that his decision is not the result of any disagreement with the Company. The Company and the Board express their appreciation to Mr. Siebert for this more than a decade of dedicated service on the Board. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: April 24, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3